ProStrakan Group plc has announced the approval of Sancusso – a transdermal patch for the prevention of chemotherapy-induced nausea and vomiting.
The US Food and Drug Administration gave the green flag on ProStrakan’s novel new product, which is the world’s first liscensed transdermal 5HT receptor antagonist.
ProStrakan Group plc hope to launch Sancusso in the US before the end of 2008 into a market worth USD 1.3 billion. It will be the first ever product from the international speciality pharmaceutical company, to be launced in the United States.
Dr Wilson Totten, CEO at ProStrakan commented on the news: “FDA approval of Sancusso means that ProStrakan remains on track to launch its first product in the US, the worlds largest pharmaceutical market, later this year. This is a very significant breakthrough, both for patients and ProStrakan.”
Sancusso – which has been manufactured in the form of a patch – has been developed to help cancer sufferers who are at risk of severe nausea and vomiting, by providing them with a patient friendly, non-invasive alternative to other treatments, such as oral intake treatments.
Dr Wilson Totten also said: “The launch will make Sancusso available for the first time to prevent nausea and vomiting in chemotherapy patients. Significant challenges persist in the prevention of CINV, which jeopardises the health of many chemotherapy patients and can deter them from continuing their cancer treatment.”
At present, ProStrakan are discussing plans to file for two further drug applications with the FDA in the US for Fortigel and Cellegesic.